ImmunoCult™-XF T Cell Expansion Medium

Serum-free and xeno-free medium for the expansion of T cells

ImmunoCult™-XF T Cell Expansion Medium

Serum-free and xeno-free medium for the expansion of T cells

From: 233 USD
Catalog #
(Select a product)
Serum-free and xeno-free medium for the expansion of T cells
Add to Wish List

Product Advantages


  • No need to supplement the medium with serum

  • Supports robust T cell expansion with high viability after 10 - 12 days of culture

  • Expanded T cells are able to produce cytokines including IFN-gamma and IL-4 upon restimulation

  • Use with ImmunoCult™ Human T Cell Activators (Catalog #10970 and 10971) for bead-free activation of T cells

Overview

ImmunoCult™-XF T Cell Expansion Medium is a serum-free and xeno-free medium optimized for the in vitro culture and expansion of T cells isolated from peripheral blood. Recombinant cytokines, required for the optimal growth and expansion of T cells, have not been added to ImmunoCult™-XF T Cell Expansion Medium. This allows users the flexibility to prepare medium that meets their requirements.

This product is designed for research applications. If you require reagents suitable for use in cell therapy manufacturing, ImmunoCult™-XF (Catalog #100-0956) is produced under relevant GMPs for use in clinical applications.
Subtype
Specialized Media
Cell Type
T Cells, T Cells, CD4+, T Cells, CD8+
Species
Human, Mouse
Application
Cell Culture, Expansion
Brand
ImmunoCult
Area of Interest
Drug Discovery and Toxicity Testing, Immunology, Cell Therapy Development
Formulation Category
Serum-Free, Xeno-Free

Data Figures

ImmunoCult™-XF T Cell Expansion Medium Supports Faster T Cell Expansion Than Other Serum-Free and Serum-Supplemented Media

Figure 1. ImmunoCult™-XF T Cell Expansion Medium Supports Faster T Cell Expansion Than Other Serum-Free and Serum-Supplemented Media

T cells were isolated from human peripheral blood samples using the EasySep™ Human T Cell Isolation Kit (Catalog #17951), stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator (Catalog #10970), and cultured in ImmunoCult™-XF T Cell Expansion Medium supplemented with rhIL-2. T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator on day 0 and every 7 to 8 days for the duration of the culture. T cells were analyzed on days 4, 7, 8, 10, 11, 14, 18, and 21 for fold expansion relative to the initial cell seeding density. Compared to all competitor media tested, ImmunoCult™-XF T Cell Expansion Medium showed significantly higher expansion of total T cells. Competitors 1 to 4 include, in no particular order, X-VIVO™ 15 (Lonza), AIM V® Medium (Life Tech), CellGro® DC Medium (CellGenix), and RPMI 1640 + serum. Each data point represents the mean fold expansion ± S.E.M. at the specified time points (p<0.05 for ImmunoCult™-XF versus all media for days 8, 11, 14, 18, and 21, tested using two-tailed, paired t-test with unequal variance, n = 6 to 19 donors). The average fold expansion of T cells in ImmunoCult™-XF T Cell Expansion Medium were 15-fold on day 7, 80-fold on day 10, 450-fold on day 14, and 4,000-fold on day 21.

ImmunoCult™-XF T Cell Expansion Medium Supports Greater T Cell Expansion Than Other Serum-Free and Serum-Supplemented Media

Figure 2. ImmunoCult™-XF T Cell Expansion Medium Supports Greater T Cell Expansion Than Other Serum-Free and Serum-Supplemented Media

T cells were isolated from human peripheral blood samples using the EasySep™ Human T Cell Isolation Kit (Catalog #17951), stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator (Catalog #10970), and cultured in (A) ImmunoCult™-XF T Cell Expansion Medium or serum-free competitor media with rhIL-2 in three replicate cultures per donor, or cultured in (B) ImmunoCult™-XF T Cell Expansion Medium or serum-supplemented competitor media with rhIL-2 in three replicate cultures per donor. T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator on day 0 and every 7 to 8 days for the duration of the culture. T cells were analyzed on day 21 for fold expansion relative to the initial cell seeding density.
(A) Compared to all serum-free competitor media tested, ImmunoCult™-XF T Cell Expansion Medium showed significantly higher expansion of total T cells. Competitors 1 to 6 represent serum-free competitor media, which include, in no particular order, X-VIVO™ 15 (Lonza), AIM V® Medium (Life Tech), CellGro® DC Medium (CellGenix), CTS™ OpTmizer™ T Cell Expansion SFM (Life Tech), TexMACS™ Medium (Miltenyi), and PRIME-XV® T Cell Expansion XSFM (Irvine Scientific). Each column with error bars represents the mean ± S.E.M. (p<5x10-13 for ImmunoCult™-XF T Cell Expansion Medium versus all other serum-free media, tested using the linear mixed effect model with linear regression, n = 4 to 19 donors).
(B) Compared to all serum-supplemented competitor media tested, ImmunoCult™-XF T Cell Expansion Medium showed similar or significantly higher expansion of total T cells. Competitors 1 to 4 represent serum-supplemented competitor media, which include, in no particular order, X-VIVO™ 15 + serum, CTS™ OpTmizer™ T Cell Expansion SFM + serum, RPMI 1640 + serum, and IMDM + serum. Each column with error bars represents the mean ± S.E.M. (p<0.0006 for ImmunoCult™-XF T Cell Expansion Medium versus all other serum-supplemented media except for Competitor 4, tested using the linear mixed effect model with linear regression, n = 1 to 19 donors).

T Cells Expanded in ImmunoCult™-XF T Cell Expansion Medium Show Similar Proportions of CD4+ and CD8+ Cells as T Cells at the Start of Culture

Figure 3. T Cells Expanded in ImmunoCult™-XF T Cell Expansion Medium Show Similar Proportions of CD4+ and CD8+ Cells as T Cells at the Start of Culture

T cells were isolated from human peripheral blood samples using the EasySep™ Human T Cell Isolation Kit (Catalog #17951), stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator (Catalog #10970), and cultured in ImmunoCult™-XF T Cell Expansion Medium supplemented with rhIL-2. T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator on day 0 and every 7 to 8 days for the duration of the culture. On day 0 and day 21, T cells were harvested and analyzed for (A) CD4+ and (B) CD8+ expression. Each column with error bars represents the mean ± S.E.M. (n = 24 donors for day 0 and n = 19 donors for day 21).

T Cells Expanded in ImmunoCult™-XF T Cell Expansion Medium Produce Intracellular IFN-gamma and IL-4

Figure 4. T Cells Expanded in ImmunoCult™-XF T Cell Expansion Medium Produce Intracellular IFN-gamma and IL-4

T cells were isolated from human peripheral blood samples using the EasySep™ Human T Cell Isolation Kit (Catalog #17951), stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator (Catalog #10970), and cultured in ImmunoCult™-XF T Cell Expansion Medium supplemented with rhIL-2. T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator on day 0 and every 7 to 8 days for the duration of the culture. On day 21, T cells were harvested and analyzed for intracellular IFN-gamma and IL-4 after stimulation with PMA and ionomycin for 4 hours and with Brefeldin A for 2 hours. The production of IFN-gamma and IL-4 in CD3+, CD3+CD4+CD8-, and CD3+CD4-CD8+ cells were determined. Each stacked column with error bars represents the mean ± S.E.M. (n = 9 donors).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
10981
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
10981
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (33)

Publications (48)

Butyrate enhances tumor immune evasion by increasing PD-L1 abundance. X. Sun et al. International journal of biological sciences 2026 Jul

Abstract

As a short-chain fatty acid and histone deacetylase (HDAC) inhibitor, butyrate possesses extensive immunomodulatory properties. Here, we uncover a novel mechanism wherein butyrate markedly upregulates the expression of the immune checkpoint PD-L1 across diverse tumor cell types. Mechanistically, epigenetic analyses revealed that butyrate drives PD-L1 transcriptional activation through dual synergistic pathways: increasing histone H3 acetylation (H3Ac) at the PD-L1 promoter via HDAC inhibition, and enhancing histone H3K4me3 modification by upregulating transglutaminase 2 (TGM2). Combining butyrate or high-fiber diets with anti-PD-L1 antibodies profoundly suppressed tumor growth and bolstered anti-tumor immunity in both subcutaneous and AOM-DSS-induced colorectal cancer (CRC) murine models. Ultimately, our results highlight butyrate and dietary fiber supplementation as promising sensitizing strategies to augment the efficacy of PD-L1 blockade in patients with low baseline PD-L1 expression.
Natural Killer Cell-Derived Extracellular Vesicles Exhibit Cytotoxicity Against Bulk Tumor Cells and Cancer Stem Cells in Triple-Negative Breast Cancer M. Kirkby et al. Nanomaterials 2026 Apr

Abstract

Triple-negative breast cancer (TNBC) remains a significant challenge in oncology, contributing to a significant portion of cancer-related deaths among women. Current therapeutic options, including chemotherapy, surgery, radiation, and hormonal targeting therapies, exhibit limited efficacy, necessitating the exploration of innovative treatment modalities. The emergence of drug resistance and the persistence of cancer stem cells (CSCs) further emphasize the urgent need for novel therapeutic strategies. In this context, natural killer cell-derived extracellular vesicles (NK-EVs) have emerged as a promising cell-free therapeutic approach that exhibits high tumor infiltration and cytotoxicity against cancer cells and CSCs. This study aims to investigate the efficacy of NK-EVs as a therapeutic strategy for TNBC using various clinically relevant models, including patient-derived xenografts. Pathway analysis suggests strong activation of apoptosis via canonical caspase activation, as well as necrosis, thereby confirming the important cytotoxic effect of NK-EVs. Interestingly, NK-EVs were also found to suppress TNBC CSCs by disrupting their functionality and viability, and NK-EV treatment increased the expression of apoptosis markers in both CSCs and non-CSCs. By elucidating the therapeutic efficacy and translational potential of NK-EV-based interventions in TNBC, these findings offer critical insights for the development of future immunotherapeutic strategies against this aggressive subtype of breast cancer.
CD137L promotes immune surveillance in melanoma via HLTF regulation L. Liang et al. Nature Communications 2025 Sep

Abstract

Immune checkpoint blockers (ICBs) have demonstrated substantial efficacy across various malignancies, yet the benefits of ICBs are limited to a subset of patients. Therefore, it is essential to identify novel therapeutic targets. By integrating multi-omics data from cohorts of patients with melanoma treated with ICBs, a positive correlation is observed between tumor CD137L expression and the efficacy of PD-1 blockade. Functionally, CD137L induction in cancer cells significantly enhances anti-tumor immunity by promoting CD8 + T cell survival, both in vivo and in vitro. Mechanistically, helicase-like transcription factor (HLTF) is identified as a pivotal transcriptional regulator of CD137L , controlling its expression through phosphorylation of serine at position 398. Therapeutically, the AMPK agonist AICAR (acadesine) as an inducer of CD137L , exhibiting synergistic effects with PD-1 or CTLA-4 blockade. In summary, our findings elucidate a mechanism controlling CD137L expression and highlight a promising combination therapy to enhance the efficacy of ICBs in melanoma. One Sentence Summary: Inducing co-stimulatory immune checkpoint CD137L expression in melanoma cells enhances T cell-mediated anti-tumor immunity. Subject terms: Tumour immunology, Cancer immunotherapy